Cite
MLA Citation
Naomi B Haas et al.. “Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial.” Journal for immunotherapy of cancer, vol. 3, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100135180788.0x000005